The characteristics of breast cancer subtypes: Implications for treatment guidelines and individualized treatment strategies in China

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 5, 2014, Pages 383-389

  Zheng, Shan ^a   Song, Qing Kun ^a   Ren, Yu ^b   Feng, Wei Liang ^c   Kong, Ya Nan ^d   Huang, Rong ^a,e   Xu, Feng ^f   Li, Jing ^a   Zhang, Bao Ning ^a   Fan, Jin Hu ^a   He, Jian Jun ^b   Qiao, You Lin ^a  

^a CANCER HOSPITAL   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e SICHUAN UNIVERSITY   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Age; Breast carcinoma; Nationwide; Regional socioeconomic status; Subtype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA UROGASTRONE; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CHINA; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; SOCIAL STATUS; TRIPLE NEGATIVE BREAST CANCER; AGE; AGED; BREAST NEOPLASMS; CARCINOMA; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; SOCIOECONOMICS; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CHINA; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; TUMOR BURDEN; YOUNG ADULT;

EID: 84900507685     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182a3c52c     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
3. Wesolowski R, Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr. 2011; 15: 105-115.
4. Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012; 23(suppl 6): vi19-vi22.
5. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 2009; 59: 303-313.
6. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol. 2008; 26: 2373-2378.
7. Caldarella A, Crocetti E, Bianchi S, et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res. 2011; 17: 753-758.
8. Garcia Fernandez A, Gimenez N, Fraile M, et al. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry: a single institution survey spanning 1998 to 2010. Breast. 2012; 21: 366-373.
9. Chen XY, Kong ZL. Chinese Cancer Registry Annual Report 2009. Beijing: Military Medical Science Press; 2010.
10. National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health (2010). National survey on cancer mortality in China-the third sample survey on mortality.
11. He J, Zhao P, Chen WQ. Chinese Cancer Registry Annual Report 2011. Beijing: Military Medical Science Press; 2012.
12. Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 2011; 11: 364.
13. Zheng S, Bai JQ, Li J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999-2008: a national-wide multicenter cross-sectional image over 10 years. Int J Cancer. 2012; 131: 2622-2631.
14. Porter PL. Global trends in breast cancer incidence and mortality. Salud Publica Mex. 2009; 51(suppl 2): s141-s146.
15. American Joint Committee on Cancer. AJCC Cancer Staging Manual. Philadelphia: Lippincott-Raven; 1997.
16. American Joint Committee on Cancer. AJCC Cancer Staging Manual. New York: Springer; 2002.
17. World Health Organization. Histological Typing of Breast Tumors. Geneva: World Health Organization; 1981.
18. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC; 2003.
19. Zarbo RJ, Hammond ME. Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003; 127: 549-553.
20. IARC. Breast cancer in different regions GLOBOCAN, 2008. Available at: http://globocan.iarc.fr.IARC. Accessed July 25, 2013.
21. Wang Q, Li J, Zheng S, et al. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012; 12: 122.
22. Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011; 11: 292.
23. Lin CH, Liau JY, Lu YS, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1807-1814.
24. Wang Y, Yin Q, Yu Q, et al. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat. 2011; 130: 489-498.
25. Xue C, Wang X, Peng R, et al. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci. 2012; 103: 1679-1687.
26. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010; 27: 926-931.
27. Kim RG, Kim EK, Kim HA, et al. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. Eur J Surg Oncol. 2011; 37: 629-634.
28. Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010; 10: 507.
29. Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2010; 17: 118-124.
30. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37: 1217-1226.
31. Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007; 16(suppl 2): S72-S77.
32. Spitale A, Mazzola P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009; 20: 628-635.
33. Durbecq V, Ameye L, Veys I, et al. A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol. 2008; 67: 80-92.
34. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 439-443.
35. Crabb SJ, Cheang MC, Leung S, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008; 8: 249-256.
36. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
37. Munoz M, Fernandez-Acenero MJ, Martin S, et al. Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet. 2009; 280: 43-48.
38. Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010; 34: 2308-2324.
39. Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012; 30: 1879-1887.
40. Jatoi I, Anderson WF, Rosenberg PS. Qualitative age-interactions in breast cancer: a tale of two diseases? Am J Clin Oncol. 2008; 31: 504-506.
41. Anderson WF, Jatoi I, Sherman ME. Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol. 2009; 27: 5308-5311.
42. Jatoi I, Anderson WF. Qualitative age interactions in breast cancer studies: a mini-review. Future Oncol. 2010; 6: 1781-1788.
43. Department of Health, Executive Yuan, Republic of China (Taiwan). Health and national health insurance annual statistics information service, 2006. Available at: http://www.doh.gov.tw/statistic/index.html. Accessed August 18, 2006.
44. Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008; 112: 737-747.
45. Salhia B, Tapia C, Ishak EA, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health. 2011; 11: 44.
46. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009; 18: 883-893.
47. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948.